ProUroCare Medical Inc. · OTC:PUMD
ProUroCare Medical — Shareholder Meeting (August 2013)
8 slides from ProUroCare Medical's shareholder meeting presentation, Aug 22, 2013
Slide 1: Shareholders Meeting
Shareholders Meeting August 22, 2013 CONFIDENTIAL 1
Slide 2: Safe-Harbor Statement
Safe-Harbor Statement This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or simi
Slide 3: Summary of Past 12 Month Accomplishments
Summary of Past 12 Month Accomplishments Despite being hampered by inadequate funding the company completed several key initiatives during the past twelve months: • Probe design modifications to achieve reusable probe were completed • Design requirements and quotes for next two generation systems in
Slide 4: Future Operational Objectives and Milestones
Future Operational Objectives and Milestones The following timelines are from when adequate funding is available: • Complete the build and testing of reusable probes, submit and receive FDA 510K approval – 8 Months • Place the existing four systems at key clinical sites, train centers and initiate c
Slide 5: Current Funding Initiatives
Current Funding Initiatives 1. Short-term Bridge funding - $300K to enable ongoing operations & cover overhead expenses 2. The $ 1.5 Million secured offering to complete reusable probe testing and FDA 510K clearance and place four existing systems 3. Continue search for one or more of US and non-US
Slide 6: Increasing Concerns of Treatment Overuse
Increasing Concerns of Treatment Overuse There are growing concerns and scrutiny of Treatment Overuse – • In May, 2013 AUA recommendations to not use PSA testing in additional age groups • In June, 2013 publication reports up to 60% of US prostate cancer interventions (surgical, radiation, chemo, et
Slide 7: Active Surveillance Illustration
Active Surveillance Illustration Smaller, contained abnormality Abnormality increased in size, approaching the prostate wall ProUroScan could monitor changes in abnormality size and location to minimize treatment when it is not warranted and reduce patient anxiety while deferring treatment CONFIDENT
Slide 8: Questions?
Q and A Questions? CONFIDENTIAL 8
ProUroCare Medical — Shareholder Meeting (August 2013) on 6ix